[go: up one dir, main page]

MX2022004734A - Metodos para tratar trastornos del desarrollo con gaboxadol. - Google Patents

Metodos para tratar trastornos del desarrollo con gaboxadol.

Info

Publication number
MX2022004734A
MX2022004734A MX2022004734A MX2022004734A MX2022004734A MX 2022004734 A MX2022004734 A MX 2022004734A MX 2022004734 A MX2022004734 A MX 2022004734A MX 2022004734 A MX2022004734 A MX 2022004734A MX 2022004734 A MX2022004734 A MX 2022004734A
Authority
MX
Mexico
Prior art keywords
syndrome
methods
gaboxadol
disorder
developmental disorders
Prior art date
Application number
MX2022004734A
Other languages
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2022004734A publication Critical patent/MX2022004734A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan métodos para tratar trastornos del desarrollo tales como síndrome de Angelman, síndrome X frágil, sindrome de temblor/ataxia asociado a X frágil (FXTAS), trastorno de espectro autista, autismo, sindrome de Asperger, trastorno generalizado del desarrollo, trastorno desintegrativo infantil, síndrome de Rett, síndrome de Lanau-Kleffner, síndrome de Prader-Willi, discinesia tardía y/o síndrome de Williams con gaboxadol o una sal farmacéuticamente aceptable de la misma. Los métodos proporcionan composiciones terapéuticas que pueden usarse para mejorar uno o más síntomas del trastorno del desarrollo.
MX2022004734A 2015-07-17 2018-01-17 Metodos para tratar trastornos del desarrollo con gaboxadol. MX2022004734A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562193717P 2015-07-17 2015-07-17
US201562207595P 2015-08-20 2015-08-20
US201662332567P 2016-05-06 2016-05-06
US201662346763P 2016-06-07 2016-06-07
US15/209,862 US20170014393A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol

Publications (1)

Publication Number Publication Date
MX2022004734A true MX2022004734A (es) 2022-05-13

Family

ID=57774846

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000745A MX391708B (es) 2015-07-17 2016-07-14 Metodos para tratar trastornos del desarrollo con gaboxadol.
MX2022004734A MX2022004734A (es) 2015-07-17 2018-01-17 Metodos para tratar trastornos del desarrollo con gaboxadol.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018000745A MX391708B (es) 2015-07-17 2016-07-14 Metodos para tratar trastornos del desarrollo con gaboxadol.

Country Status (17)

Country Link
US (8) US20170014393A1 (es)
EP (2) EP3324961B1 (es)
JP (3) JP2018520189A (es)
KR (2) KR20240160666A (es)
CN (2) CN116531370A (es)
AU (2) AU2016295138B2 (es)
BR (1) BR112018000933A2 (es)
CA (1) CA2992734A1 (es)
CL (1) CL2018000142A1 (es)
CO (1) CO2018000375A2 (es)
ES (1) ES3021189T3 (es)
HK (1) HK1250951A1 (es)
IL (2) IL256912B2 (es)
MX (2) MX391708B (es)
PE (2) PE20230735A1 (es)
TW (2) TWI819995B (es)
WO (1) WO2017015049A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62007B1 (sr) * 2014-06-06 2021-07-30 Ovid Therapeutics Inc Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma
IL256912B2 (en) 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
CN109715151A (zh) 2016-08-11 2019-05-03 奥维德医疗公司 用于治疗癫痫性紊乱的方法和组合物
CN110225754A (zh) * 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
AU2018309049A1 (en) 2017-08-04 2020-02-27 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
IL274431B2 (en) * 2017-11-14 2024-06-01 Sk Biopharmaceuticals Co Ltd Use of carbamate compound for reducing or treating developmental disorders including fragile x syndrome, angelman syndrome or rett syndrome
US10704048B2 (en) 2018-06-14 2020-07-07 Ovid Therapeutics Inc. Use of MIR-92A or MIR-145 in the treatment of Angelman syndrome
AU2019326539A1 (en) * 2018-08-22 2021-03-11 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma
EP3833351A4 (en) * 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL FOR THE TREATMENT OF GILLES DE LA TOURETTE SYNDROME, TICS AND STATTING
BR112021009946A2 (pt) * 2018-11-21 2021-08-17 Certego Therapeutics Inc. combinação de gaboxadol e lítio para o tratamento de distúrbios psiquiátricos
WO2020106927A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
US11690829B2 (en) 2018-12-17 2023-07-04 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
EP3979985A4 (en) * 2019-06-07 2023-05-03 Paxmedica, Inc. COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS
WO2021011597A1 (en) * 2019-07-15 2021-01-21 Ovid Therapeutics Inc. Pharmaceutical formulations containing gaboxadol for therapeutic treatment
MX2022007715A (es) 2019-12-18 2022-07-19 Ovid Therapeutics Inc Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36.
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
WO2002043731A2 (en) * 2000-11-30 2002-06-06 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
UA80092C2 (en) 2001-05-21 2007-08-27 Lundbeck & Co As H Granular preparations of gaboxadol, process for the preparation thereof and pharmaceutical composition
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
AU2004248890A1 (en) 2003-06-25 2004-12-29 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
US20050234093A1 (en) 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
WO2005023256A1 (en) 2003-09-10 2005-03-17 Merck Sharp & Dohme Limited Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
WO2005063248A1 (en) 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
KR20070010136A (ko) * 2004-04-02 2007-01-22 하. 룬트벡 아크티에 셀스카브 가복사돌을 이용한 손상된 호흡 기능의 치료
AU2005229493A1 (en) * 2004-04-02 2005-10-13 H. Lundbeck A/S Treatment of impaired respiratory function with gaboxadol
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
WO2007053596A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
DK2083811T3 (en) * 2006-11-22 2017-01-30 Clinical Res Ass Llc PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
US20090269795A1 (en) 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
US20090048288A1 (en) 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
EP2334299A1 (en) 2008-09-01 2011-06-22 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat
US20100286762A1 (en) 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
CN102147667A (zh) 2010-02-08 2011-08-10 深圳富泰宏精密工业有限公司 触控笔
CN107050456B (zh) 2010-09-28 2022-08-12 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
US20130309306A1 (en) 2010-12-01 2013-11-21 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
US9480695B2 (en) 2011-09-29 2016-11-01 The University Of Tokyo Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder
WO2013056159A1 (en) 2011-10-13 2013-04-18 Jaleva Pharmaceuticals, Llc Methods and compositions for rapid transbuccal delivery of active agents
JP2016501876A (ja) * 2012-11-30 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロイドの抗痙攣活性
WO2014123909A1 (en) 2013-02-05 2014-08-14 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
RS62007B1 (sr) * 2014-06-06 2021-07-30 Ovid Therapeutics Inc Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma
US9802945B2 (en) 2014-06-12 2017-10-31 Pfizer Limited Imidazopyridazine derivatives as modulators of the GABAA receptor activity
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
IL256912B2 (en) 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
AU2016304737B2 (en) 2015-08-11 2021-03-11 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
CA3002831C (en) 2015-10-22 2024-04-16 Cavion, Inc. Methods for treating angelman syndrome and related disorders
KR20190013737A (ko) 2016-05-26 2019-02-11 오비드 테라퓨틱스 인크. 피프라드롤을 이용한 행동 증후군들의 치료 방법들
CN109715151A (zh) 2016-08-11 2019-05-03 奥维德医疗公司 用于治疗癫痫性紊乱的方法和组合物
CN110225754A (zh) 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus

Also Published As

Publication number Publication date
AU2016295138A1 (en) 2018-02-08
AU2021250862B2 (en) 2023-11-09
ES3021189T3 (en) 2025-05-26
IL256912B2 (en) 2024-01-01
CN116531370A (zh) 2023-08-04
TW202325293A (zh) 2023-07-01
EP4541420A3 (en) 2025-06-25
EP3324961C0 (en) 2025-03-19
US20190255027A1 (en) 2019-08-22
IL305342A (en) 2023-10-01
EP3324961A4 (en) 2019-03-13
EP3324961A1 (en) 2018-05-30
WO2017015049A1 (en) 2017-01-26
US12465597B2 (en) 2025-11-11
US20230071127A1 (en) 2023-03-09
AU2021250862A1 (en) 2021-11-04
US20180098974A1 (en) 2018-04-12
MX391708B (es) 2025-03-21
MX2018000745A (es) 2018-08-15
CN108024997A (zh) 2018-05-11
BR112018000933A2 (en) 2018-09-04
US20190117632A1 (en) 2019-04-25
HK1250951A1 (zh) 2019-01-18
IL305342B1 (en) 2026-02-01
IL256912A (en) 2018-03-29
US20210030727A1 (en) 2021-02-04
CO2018000375A2 (es) 2018-04-19
EP4541420A2 (en) 2025-04-23
TWI819995B (zh) 2023-11-01
US11096929B2 (en) 2021-08-24
JP2018520189A (ja) 2018-07-26
PE20190338A1 (es) 2019-03-07
IL256912B1 (en) 2023-09-01
PE20230735A1 (es) 2023-05-03
KR20240160666A (ko) 2024-11-11
TW201707700A (zh) 2017-03-01
US20180338960A1 (en) 2018-11-29
JP2021130687A (ja) 2021-09-09
KR20180031721A (ko) 2018-03-28
CA2992734A1 (en) 2017-01-26
EP3324961B1 (en) 2025-03-19
US20190321342A1 (en) 2019-10-24
AU2016295138B2 (en) 2021-11-04
JP2023103375A (ja) 2023-07-26
CL2018000142A1 (es) 2018-07-13
US20170014393A1 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
MX2022004734A (es) Metodos para tratar trastornos del desarrollo con gaboxadol.
MX2019001937A (es) Métodos de tratamiento de trastornos del desarrollo con biguanidas.
CA2999253C (en) Heterocyclic compounds and uses thereof
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
EA201491819A1 (ru) Фармацевтические композиции для комбинированного лечения
HK1249893A1 (zh) 氘代vx-661
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
WO2015075557A3 (en) C/ebp alpha short activating rna compositions and methods of use
MX2018007704A (es) Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
NZ721952A (en) Delayed release compositions of linaclotide
MY189912A (en) Substituted xanthines and methods of use thereof
WO2015184257A3 (en) Small molecule transcription modulators of bromodomains
MX2018002906A (es) Metodos de tratamiento de trastornos del desarrollo con pipradrol.
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
WO2018191482A3 (en) Methods of treating developmental encephalopathies
EP3256143A4 (en) Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof and methods of using the same
AU2016298962A8 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
EP4342461A3 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
HK1257448A1 (zh) 包含c-c基序趋化因子22(ccl22)或其片段的疫苗组合物
AU2012280776B2 (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
WO2019103875A3 (en) Methods of using and compositions containing dulaglutide
MY200499A (en) Sulfonamide pharmaceutical composition
MX2020007162A (es) Metodos para el tratamiento de trastornos del desarrollo y/o trastornos convulsivos con etifoxina.
WO2014145126A3 (en) Methods of treating dyskinesia and related disorders
WO2016109361A3 (en) 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase